Angiographic disease progression and residual risk of cardiovascular events while on optimal medical therapy observations from the COURAGE trial

Circulation: Cardiovascular Interventions

Volumn 4, Issue 6, 2011, Pages 545-552

  Mancini, G B John ^a   Hartigan, Pamela M ^b   Bates, Eric R ^c   Sedlis, Steven P ^d   Maron, David J ^e   Spertus, John A ^f   Berman, Daniel S ^g   Kostuk, William J ^h   Shaw, Leslee J ⁱ   Weintraub, William S ^j   Teo, Koon K ^k   Dada, Marcin ^l   Chaitman, Bernard R ^m   O'Rourke, Robert A ⁿ   Boden, William E ^o  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^c UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^f UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h UNIVERSITY OF WESTERN ONTARIO   (Canada)

ⁱ EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j CHRISTIANA CARE HEALTH SYSTEM   (United States)

^k MCMASTER UNIVERSITY MEDICAL CENTRE   (Canada)

^l HARTFORD HOSPITAL   (United States)

^m SAINT LOUIS UNIVERSITY HOSPITAL   (United States)

ⁿ UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^o UNIVERSITY AT BUFFALO   (United States)

more..

Author keywords

Angiography; Angioplasty; Atherosclerotic plaque; Coronary artery disease; Revascularization; Rupture

Indexed keywords

ACUTE CORONARY SYNDROME; ADULT; ANGIOCARDIOGRAPHY; ARTICLE; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; FEMALE; FOLLOW UP; HEALTH STATUS; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; OPTIMAL MEDICAL THERAPY; PATIENT REFERRAL; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RESTENOSIS; REVASCULARIZATION; THERAPY;

ACUTE CORONARY SYNDROME; ANGIOPLASTY, BALLOON, CORONARY; CARDIOVASCULAR AGENTS; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84856093377     PISSN: 19417640     EISSN: 19417632     Source Type: Journal    
DOI: 10.1161/CIRCINTERVENTIONS.110.960062     Document Type: Article

References (16)

1. Boden WE, O'Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ, Knudtson M, Dada M, Casperson P, Harris CL, Chaitman BR, Shaw L, Gosselin G, Nawaz S, Title LM, Gau G, Blaustein AS, Booth DC, Bates ER, Spertus JA, Berman DS, Mancini GBJ, Weintraub WS; COURAGE Trial Research Group. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007;356:1503-1516. (Pubitemid 46588415)
2. Libby P, Aikawa M. Stablization of atherosclerotic plaques: new mechanisms and clinical targets. Nature Medicine. 2002;8:1257-6122.
3. Mancini GBJ, Bates ER, Maron DJ, Hartigan PM, Dada M, Gosselin G, Kostuk W, Sedlis SP, Shaw LJ, Berman DS, Berger PB, Spertus J, Mavromatis K, Knudtson M, Chaitman BR, O'Rourke RA, Weintraub WS, Teo KK, Boden WE; COURAGE Trial Investigators and Coordinators. Quantitative results of baseline angiography and percutaneous coronary intervention in the COURAGE trial. Circ Cardiovasc Qual Outcomes. 2009;2:292-293.
4. Maron DJ, Boden WE, O'Rourke RA, Hartigan PM, Calfas KJ, Mancini GBJ, Spertus JA, Dada M, Kostuk WJ, Knudtson M, Harris CL, Sedlis SP, Zoble RG, Title LM, Gosselin G, Nawaz S, Gau GT, Blaustein AS, Bates ER, Shaw LJ, Berman DS, Chaitman BR, Weintraub WS, Teo KK; COURAGE Trial Research Group. Intensive multifactorial intervention for stable coronary artery disease: optimal medical therapy in the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) trial. J Am Coll Cardiol. 2010;55: 1348-1358.
5. Sharif F, Murphy RT. Current status of vulnerable plaque detection. Catheter and Cardiovasc Intervention. 2010;75:135-144.
6. Glaser R, Selzer F, Faxon DP, Laskey WK, Cohen HA, Slater S, Detre KM, Wilensky RL. Clinical progression of incidental, asymptomatic lesions discovered during culprit vessel coronary intervention. Circulation. 2005;111:143-149. (Pubitemid 40139724)
7. Little WC, Constantinescu M, Applegate RJ, Kutcher MA, Burrows MT, Kahl FR, Santamore WP. Can coronary angiography predict the site of a subsequent myocardial infarction in patients with mild-to-moderate coronary artery disease? Circulation. 1988;78:1157-1166.
8. Stone GW, Maehara A, Lansky AJ, de Bruyne B, Cristea E, Mintz GS, Mehran R, McPherson J, Farhat N, Marso SP, Parise H, Templin B, White R, Zhang Z, Serruys PW; PROSPECT Investigators. A prospective natural-history study of coronary atherosclerosis. N Engl J Med. 2011; 364:226-235.
9. Motoyama S, Sarai M, Harigaya H, Anno H, Inoue K, Hara T, Naruse H, Ishii J, Hishida H, Wong ND, Virmani R, Kondo T, Ozaki Y, Narula J. Computed Tomographic angiography characteristics of atherosclerotic plaques subsequently resulting in acute coronary syndrome. J Am Coll Cardiol. 2009;54:49-57.
10. Tawakol A, Migrino RQ, Bashian GG, Bedri S, Vermylen D, Cury RC, Yates D, la Muraglia GM, Furie K, Houser S. In vivo 18Ffluorodeoxyglucose positron emission tomography imaging provides a noninvasive measure of carotid plaque inflammation in patients. J Am Coll Cardiol. 2006;48:1818-1824. (Pubitemid 44648622)
11. Hoffmann U, Moselewski F, Nieman K, Jang I-K, Ferencik M, Rahman AM, Cury RC, Abbara S, Joneidi-Jafari H, Achenbach S, Brady TJ. Noninvasive assessment of plaque morphology and composition in culprit and stable lesions in acute coronary syndrome and stable lesions in stable angina by multidetector computed tomography. J Am Coll Cardiol. 2006; 47:1655-1662.
12. Finn AV, Nakano M, Narula J, Kolodgie FD, Virmani R. Concept of vulnerable/unstable plaque. Arterioscler Thromb Vasc Biol. 2010;30: 1282-1292.
13. Pepine CJ. Residual risk for secondary ischemic events in patients with atherothrombotic disease: opportunity for future improvements in patient care. Ann Med. 2010;42:19-35.
14. The BARI 2D Study Group. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med. 2009;11:360: 2503-2515.
15. Tonino PAL, DeBruyne B, Pijls NHJ, Siebert U, Ikeno F, van't Veer M, Klauss V, Manoharan G, Engstrøm T, Oldroyd KG, Ver Lee PN, Mac-Carthy PA, Fearon WF; FAME Study Investigators. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention. N Engl J Med. 2009;360:213-224.
16. Pijls NHJ, Fearon WF, Tonino PAL, Siebert U, Ikeno F, Bornschein B, van't Veer M, Klauss V, Manoharan G, Engstrøm T, Oldroyd KG, Ver Lee PN, MacCarthy PA, De Bruyne B; FAME Study Investigators. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention in patients with multivessel coronary artery disease: 2-year follow-up of the FAME (Fractional Flow Reserve Versus Angiography for Multivessel Evaluation) study. J Am Coll Cardiol. 2010;56:177-184.